Astex's SGI-110 shows "clear activity" in leukemia patients

|About: Astex Pharmaceuticals, Inc. (ASTX)|By:, SA News Editor

Astex Pharmaceuticals' (ASTX) SGI-110 "showed clear activity in patients with acute myeloid leukemia" in Phase II testing.

The overall remission rate in 67 subjects was 25%.

However, no results were provided for patients with Myelodysplastic syndromes (MDS), a group of blood and bone marrow disorders, who were also part of the trial.

Shares +12.2%.